Bristol Myers Squibb Co. agreed to pay $4.1 billion to acquire Turning Point Therapeutics Inc., the developer of a drug for lung cancer that’s expected to launch next year. https://www.bloomberg.com/news/articles/2022-06-03/bristol-myers-to-pay-4-1-billion-for-lung-cancer-biotech